Jefferies raised the firm’s price target on United Therapeutics (UTHR) to $668 from $640 and keeps a Buy rating on the shares after its ADVANCE OUTCOMES study met its primary endpoint. The firm said the results potentially introduce once-daily ralinepag as a critical part of initial oral combo therapy for earlier stage of pulmonary hypertension. Jefferies added that it believes the results clearly support an approval.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- United Therapeutics price target raised to $615 from $600 at Leerink
- United Therapeutics’ Ralinepag Trial Success Boosts PAH Outlook
- United Therapeutics says phase 3 ADVANCE OUTCOMES study met its primary endpoint
- United Therapeutics Earnings Call Signals Growth Ahead
- MannKind downgraded to Sector Perform from Outperform at RBC Capital